The NeoADAURA is a phase III study comparing neoadjuvant osimertinib with or without chemotherapy to chemotherapy alone in patients with resectable, EGFR-mutated, stage II–IIIB NSCLC, with a major pathological response as the primary end point [107]. Here, EGFR is linked to non-small cell lung carcinoma.